Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 3510
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lenz, H. J. Articles by Van Cutsem, E. Search for Related Content PubMed Articles by Lenz, H. J. Articles by Van Cutsem, E.

Abstract

Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

USC Norris Cancer Center, Los Angeles, CA; Dana Farber Cancer Institute, Boston, MA; Sweedish Cancer Institute, Seattle, WA; Center for Oncology Research and Treatment, Dallas, TX; St. Joseph Mercy Hospital, Ann Arbor, MI; Rocky Mountain Cancer Center, Denver, CO; Lakeland Regional Cancer Center, Lakeland, FL; ImClone Systems, Somerville, NJ; University Hospital Gasthuisberg, Leuven, Belgium

3510

Background: Cetuximab (Erbitux) has demonstrated activity in patients with epidermal growth factor receptor (EGFR) expressing colorectal cancer (CRC) refractory to irinotecan (CPT-11) both as a single agent and in combination with irinotecan. This phase II study was designed to explore the activity of cetuximab in patients with EGFR+ CRC refractory to both CPT-11 and oxaliplatin (ox). Cetuximab is a chimeric monoclonal antibody that binds specifically to the EGFR preventing homo and heterodimerization and signal transduction. Methods: Patients were treated with cetuximab at standard doses 400 mg/m² loading dose over 2 hours, then 250 mg/m² over 1 hour weekly. Results: 350 patients with EGFR + CRC who had failed both CPT-11 and ox were enrolled. Median age 59; M:F::55:45; ECOG performance status 0:1::42:57. The most commonly encountered adverse events were an acne-like skin rash (84% any grade, 5% grade 3) and fatigue/malaise (40% any grade, 9% grade 3/4). Three patients experienced a grade 3/4 allergic reaction requiring discontinuation of study treatment. Partial responses (PR) were observed in 12% of patients (28/235; 95% CI 8–17). 34% of patients had stable disease for at least 6 weeks bringing the disease control rate to 46%. Prior to an amendment to the protocol 9 patients with EGFR negative CRC were enrolled, 2 of whom had a PR. Conclusions: Cetuximab was well tolerated in this patient population and produced major objective responses in 12% of patients who had exhausted all available treatment options for metastatic colorectal cancer. This result is consistent with results reported by Saltz (ASCO 2002) and Cunningham (ASCO 2003).

Author Disclosure

Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ImClone Systems ImClone Systems ImClone Systems Bristol-Myers Squibb ImClone Systems

Abstract presentation from the 2004 ASCO Annual Meeting